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Introduction {#acn3639-sec-0005}
============

Alzheimer\'s disease (AD) is the leading cause of dementia, affecting an increasing number of people each year. AD has a strong genetic component with apolipoprotein E (*APOE)* being established as the strongest genetic risk factor for the late onset form of AD.[1](#acn3639-bib-0001){ref-type="ref"} Three alleles in the *APOE* gene, *ε*2, *ε*3, and *ε*4 differ in two single‐ nucleotide polymorphisms (SNPs), rs7412 and rs429358, and encode different apolipoprotein E (ApoE) protein isoforms.[2](#acn3639-bib-0002){ref-type="ref"} The presence of the *APOE ε*4 allele considerably increases the risk and lowers the age of onset of AD, while the *APOE ε*2 allele significantly decreases the AD risk.[1](#acn3639-bib-0001){ref-type="ref"} ApoE is a multifunctional protein that has an important role in modulating plasma lipid and lipoprotein levels as well as inflammatory responses in the brain and periphery.[3](#acn3639-bib-0003){ref-type="ref"}, [4](#acn3639-bib-0004){ref-type="ref"}, [5](#acn3639-bib-0005){ref-type="ref"} Binding of ApoE to low‐density lipoprotein (LDL) receptors in the liver mediates the clearance of chylomicrons and LDL from the bloodstream. Amino acid substitutions directly affect the function of the protein. For example, the affinity of ApoE2 to the LDL receptors is markedly reduced compared to ApoE3 and E4.[6](#acn3639-bib-0006){ref-type="ref"} Carriers of the *APOE ɛ*4 allele have higher total cholesterol levels as compared to those without the *APOE ɛ*4 allele.[4](#acn3639-bib-0004){ref-type="ref"}, [5](#acn3639-bib-0005){ref-type="ref"} In addition, the presence of the *APOE ɛ*4 allele has been suggested to augment pathophysiological states, such as oxidative stress and neuroinflammation.

Neurodegeneration in AD is linked to the accumulation of soluble oligomeric amyloid‐*β* (A*β*) in the brain. In particular, A*β* peptides of 42 amino acids in length (A*β*42) are considered the key mediators of synaptotoxicity and neurotoxicity in AD.[7](#acn3639-bib-0007){ref-type="ref"} According to the prevailing amyloid‐cascade hypothesis, A*β* deposition in the brain triggers the hyperphosphorylation of tau and its accumulation as neurofibrillary tangles, activation of inflammatory cells and pathways, initiation of oxidative stress, and decline in synaptic and neuronal health and finally neurodegeneration.[8](#acn3639-bib-0008){ref-type="ref"} This view recently gained further support from the identification of a protective *APP* variant (A673T), which was later shown to reduce A*β* levels and protect against cognitive decline.[9](#acn3639-bib-0009){ref-type="ref"}, [10](#acn3639-bib-0010){ref-type="ref"} Physiologic functions of A*β* are not well‐established, but significant lines of evidence suggest that A*β* may have potential protective properties under certain conditions. A*β*42 has been shown to have antioxidant effects and decrease the oxidation of lipoproteins in the cerebrospinal fluid (CSF) and blood plasma.[11](#acn3639-bib-0011){ref-type="ref"}, [12](#acn3639-bib-0012){ref-type="ref"} A study utilizing different experimental autoimmune encephalomyelitis models, demonstrated that the peripherally augmented levels of A*β*40 and A*β*42 effectively suppressed inflammation in different organs, thus attenuating autoimmune inflammation targeting the central nervous system (CNS).[13](#acn3639-bib-0013){ref-type="ref"} A*β*42 was recently shown to confer protection against microbial infections in various in vitro and in vivo AD models, suggesting a potential dual defensive/injurious role for A*β*42.[14](#acn3639-bib-0014){ref-type="ref"} Accordingly, A*β*42 is upregulated upon injury, inflammation and stress conditions in the brain, suggesting that especially A*β*42 may exert either protective or anti‐inflammatory effects depending on the prevailing conditions.[13](#acn3639-bib-0013){ref-type="ref"}, [15](#acn3639-bib-0015){ref-type="ref"}, [16](#acn3639-bib-0016){ref-type="ref"} Here, we have assessed the association of the different *APOE* genotypes and plasma A*β* levels with a large number of cardiovascular, metabolic health, and inflammation‐related parameters in large population‐based cohorts from Finland.

Subjects and Methods {#acn3639-sec-0006}
====================

Subjects {#acn3639-sec-0007}
--------

The study included a subset of 4913 nondiabetic men from the large population‐based Metabolic Syndrome in Men (METSIM) cohort consisting of 10,197 men in total. The participants have been randomly selected form the population register of Kuopio, Eastern Finland, and were aged 45--70 years at baseline. Participants of the study have been extensively characterized for risk factors of metabolic syndrome, type 2 diabetes and cardiovascular disease. Table [1](#acn3639-tbl-0001){ref-type="table"} presents clinical characteristics and laboratory characteristics of the study cohort. The study design has been described in detail previously.[17](#acn3639-bib-0017){ref-type="ref"} Individuals diagnosed at the baseline with AD (*n* = 3) were excluded from this study. There were no diabetic individuals in the METSIM cohort from which the *APOE* genotype information was available (Table [1](#acn3639-tbl-0001){ref-type="table"}). The METSIM study was approved by the Ethics Committee of the University of Kuopio and Kuopio University Hospital and was conducted in accordance with the Helsinki Declaration. All individuals provided written informed consent.

###### 

Clinical and laboratory characteristics of the METSIM Study participants

                                     *ε*2*ε*2 and *ε*2*ε*3   *ε*2*ε*4        *ε*3*ε*3        *ε*3*ε*4          *ε*4*ε*4        *P*
  ---------------------------------- ----------------------- --------------- --------------- ----------------- --------------- ----------------
  Number of individuals              317 (6.5%)              69 (1.4%)       2921 (59.5%)    1427 (29.0%)      179 (3.6%)      
  Age (years)                        57.1 ± 7.1              58.1 ± 7.0      56.9 ± 6.8      56.8 ± 6.9        57.1 ± 7.0      0.56
  BMI (kg/m^2^)                      26.9 ± 3.5              27.5 ± 4.4      26.9 ± 3.8      26.9 ± 3.7        26.1 ± 3.6      0.05
  Blood pressure parameters                                                                                                    
  Systolic blood pressure (mmHg)     136.7 ± 14.9            137.6 ± 14.9    136.7 ± 16.3    137.1 ± 16.0      138.3 ± 16.6    0.72
  Diastolic blood pressure (mmHg)    87.4 ± 8.8              86.8 ± 8.8      87.3 ± 9.4      87.2 ± 9.4        87.7 ± 9.8      0.97
  Lipid and lipoprotein parameters                                                                                             
  Total cholesterol (mmol/L)         5.13 ± 0.92             5.14 ± 0.94     5.36 ± 0.99     5.46 ± 1.00       5.46 ± 0.95     1.19 × 10^−6^
  LDL cholesterol (mmol/L)           3.06 ± 0.76             3.04 ± 0.84     3.38 ± 0.86     3.48 ± 0.89       3.48 ± 0.85     6.43 × 10^−15^
  HDL cholesterol (mmol/L)           1.49 ± 0.38             1.62 ± 0.50     1.46 ± 0.40     1.43 ± 0.38       1.40 ± 0.40     3.39 × 10^−4^
  Total triglycerides (mmol/L)       1.55 ± 1.68             1.41 ± 0.76     1.37 ± 1.02     1.46 ± 0.95       1.46 ± 0.86     1.21 × 10^−3^
  ApoB (g/L)                         0.97 ± 0.23             0.96 ± 0.28     1.04 ± 0.27     1.08 ± 0.28       1.10 ± 0.27     3.55 × 10^−12^
  Glucose metabolism parameters                                                                                                
  Fasting plasma glucose (mmol/L)    5.7 ± 0.5               5.7 ± 0.5       5.7 ± 0.5       5.7 ± 0.5         5.7 ± 0.5       0.77
  2 h OGTT plasma glucose (mmol/L)   6.0 ± 1.5               6.1 ± 1.8       6.1 ± 1.7       6.2 ± 1.7         6.0 ± 1.6       0.34
  Matsuda ISI (mg/dL, mU/L)          6.8 ± 3.9               7.0 ± 4.5       6.9 ± 4.1       7.0 ± 4.1         7.3 ± 4.6       0.88
  Inflammatory parameters                                                                                                      
  IL1‐RA (pg/mL)                     212.9 ± 149.2           223.0 ± 166.9   216.8 ± 163.3   217.1 ± 161.5     217.0 ± 211.0   0.67
  IL1*β* (pg/mL)                     0.35 ± 0.68             0.37 ± 0.46     0.34 ± 0.75     0.34 ± 0.63       0.38 ± 0.73     0.53
  hs‐CRP (mg/L)                      2.30 ± 4.13             2.27 ± 2.68     2.40 ± 5.43     1.65 ± 2.56       1.21 ± 1.64     8.76 × 10^−32^
                                     1.24 (2.24)\*           1.33 (2.26)\*   1.26 (2.01)\*   0.84 (1.34)\*\*   0.62 (0.99)\*   

All parameters are presented as mean ± standard deviation. For hs‐CRP the median and interquartile range (\*) are reported due to its skewed distribution. All *P*‐values except age are adjusted for age as covariate.

BMI, body mass index; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; Matsuda ISI, Matsuda insulin sensitivity index; OGTT, oral glucose tolerance test.

John Wiley & Sons, Ltd

Participants in the Finnish Geriatric Intervention study to prevent cognitive impairment and disability (FINGER) were used as a replication cohort in the study. Data from the screening/baseline FINGER visit, that is, before the start of the intervention were used for the analyses. The FINGER recruitment process has been previously described in detail.[18](#acn3639-bib-0018){ref-type="ref"}, [19](#acn3639-bib-0019){ref-type="ref"} In brief, the 1260 participants were selected from previous population‐based noninterventional surveys. Eligibility criteria were: age 60--77 years; CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least six points[20](#acn3639-bib-0020){ref-type="ref"} (Table [2](#acn3639-tbl-0002){ref-type="table"}); and cognitive performance at mean level or slightly lower than expected for age according to Finnish population norms. Individuals with dementia, substantial cognitive impairment, and conditions affecting cooperation or safe engagement in the intervention were excluded.[18](#acn3639-bib-0018){ref-type="ref"}, [19](#acn3639-bib-0019){ref-type="ref"} FINGER was approved by the coordinating ethics committee of the Hospital District of Helsinki and Uusimaa. Participants gave written informed consent at screening and baseline visits.

###### 

Clinical and laboratory characteristics of the FINGER Study participants

                                     *ε*2*ε*2 and *ε*2*ε*3       *ε*2*ε*4                    *ε*3*ε*3                    *ε*3*ε*4                    *ε*4*ε*4                    *P*
  ---------------------------------- --------------------------- --------------------------- --------------------------- --------------------------- --------------------------- ---------------
  Number of individuals              99 (8.4%)                   29 (2.5%)                   687 (58.5%)                 320 (27.2%)                 40 (3.4%)                   
  Age (years)                        69.5 ± 4.8                  68.7 ± 4.4                  69.5 ± 4.7                  69.2 ± 4.6                  67.5 ± 4.0                  0.08
  Women                              48 (48.5%)                  16 (55.2%)                  312 (45.4%)                 158 (49.4%)                 15 (37.5%)                  0.45
  BMI (kg/m^2^)                      28.0 ± 4.5                  27.4 ± 4.1                  28.4 ± 4.6                  28.2 ± 4.8                  26.3 ± 3.7                  0.03
  Blood pressure parameters                                                                                                                                                      
  Systolic blood pressure (mmHg)     137.6 ± 15.5                142.5 ± 11.3                139.7 ± 15.7                140.5 ± 17.9                141.2 ± 16.9                0.46
  Diastolic blood pressure (mmHg)    79.3 ± 8.3                  80.4 ± 6.9                  80.5 ± 9.5                  80.0 ± 10.0                 81.4 ± 10.5                 0.67
  Lipid and lipoprotein parameters                                                                                                                                               
  Total cholesterol (mmol/L)         5.06 ± 0.94                 5.35 ± 0.96                 5.10 ± 1.00                 5.26 ± 1.08                 5.46 ± 0.90                 0.05
  LDL cholesterol (mmol/L)           2.99 ± 0.81                 3.14 ± 0.84                 3.04 ± 0.84                 3.22 ± 0.96                 3.32 ± 0.81                 0.03
  HDL cholesterol (mmol/L)           1.44 ± 0.37                 1.58 ± 0.43                 1.44 ± 0.37                 1.43 ± 0.38                 1.53 ± 0.47                 0.18
  Total triglycerides (mmol/L)       1.41 ± 1.64                 1.38 ± 0.73                 1.35 ± 0.62                 1.37 ± 0.61                 1.34 ± 0.56                 0.93
  ApoB (g/L)                         0.83 ± 0.19                 0.89 ± 0.17                 0.87 ± 0.20                 0.92 ± 0.22                 0.95 ± 0.21                 6.00 × 10^−4^
  Glucose metabolism parameters                                                                                                                                                  
  Fasting plasma glucose (mmol/L)    6.1 ± 1.0                   6.0 ± 0.7                   6.1 ± 1.0                   6.1 ± 0.8                   6.0 ± 0.6                   0.86
  2 h OGTT plasma glucose (mmol/L)   7.0 ± 2.2                   6.9 ± 1.7                   7.0 ± 2.2                   7.0 ± 2.2                   6.6 ± 2.0                   0.92
  Inflammatory parameters                                                                                                                                                        
  hs‐CRP (mg/L)                      2.27 ± 5.58 1.16 (1.36)\*   2.02 ± 2.50 1.05 (1.95)\*   2.93 ± 8.62 1.23 (2.13)\*   2.37 ± 5.04 0.97 (1.67)\*   1.11 ± 1.54 0.60 (0.71)\*   1.80 × 10^−5^

All parameters except the number of individuals and gender distribution are presented as mean ± standard deviation. For hs‐CRP the median and interquartile range (\*) are reported due to its skewed distribution. All *P*‐values except age and gender are adjusted for age as covariate.

BMI, body mass index; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OGTT, oral glucose tolerance test.

John Wiley & Sons, Ltd

The neuropathological human postmortem brain cohort has been previously comprehensively described.[21](#acn3639-bib-0021){ref-type="ref"}, [22](#acn3639-bib-0022){ref-type="ref"}, [23](#acn3639-bib-0023){ref-type="ref"} In brief, temporal cortical samples were obtained from 71 individuals (18 males and 53 females; mean age, 81.0 ± 8.8 years) examined in Kuopio University Hospital (KUH). The extent of AD‐related neurofibrillary pathology was evaluated after autopsy with AT8‐immunostaining, detecting hyperphosphorylated tau.[24](#acn3639-bib-0024){ref-type="ref"} The samples were divided into three groups based on the degree of the neurofibrillary pathology according to Braak staging[24](#acn3639-bib-0024){ref-type="ref"}: Mild (Braak 0‐II, RNA *n* = 18/10 and protein *n* = 8/4 in *APOE ε*4^−^/*ε*4^+^, respectively), moderate (Braak III--IV, RNA *n* = 4/9 and protein *n* = 3/3 in *APOE ε*4^−^/*ε*4^+^, respectively), and severe (Braak V--VI, RNA *n* = 2/17 and protein *n* = 2/16 in *APOE ε*4^−^/*ε*4^+^, respectively). The study was approved by the Ethics Committee of the Kuopio University Hospital, University of Eastern Finland, the Finnish National Supervisory Authority, and the Finnish Ministry of Social Affairs and Health.

Genotyping {#acn3639-sec-0008}
----------

*APOE* genotypes based on the SNPs rs7412 and rs429358 were extracted from exome sequencing data of METSIM (Table [1](#acn3639-tbl-0001){ref-type="table"}). Individuals with *APOE ε*2*ε*2 and *ε*2*ε*3 genotypes were pooled together for the analyses. In FINGER, DNA was extracted and *APOE* genotypes were determined (Table [2](#acn3639-tbl-0002){ref-type="table"}) as described previously.[25](#acn3639-bib-0025){ref-type="ref"} DNA extraction from postmortem inferior temporal cortex and *APOE* genotyping were performed as described previously.[22](#acn3639-bib-0022){ref-type="ref"}, [23](#acn3639-bib-0023){ref-type="ref"} Temporal cortex was selected as it is the brain region known to be markedly affected in AD.[24](#acn3639-bib-0024){ref-type="ref"}

Microarray‐based expression analysis and liquid chromatography mass spectrometry‐based proteomics assay {#acn3639-sec-0009}
-------------------------------------------------------------------------------------------------------

RNA extraction from 60 human postmortem temporal cortex samples was performed as described previously.[22](#acn3639-bib-0022){ref-type="ref"}, [23](#acn3639-bib-0023){ref-type="ref"} Agilent One‐Color Microarray‐Based Exon Analysis was performed at the Finnish Microarray and Sequencing Centre in Turku and have been previously described in,[21](#acn3639-bib-0021){ref-type="ref"} identifying 19,367 unique transcripts. For transcript expression analysis, 3′ untranslated region probe signal was used as a measure of the respective transcript\'s global expression level. In case of multiple probes mapping to a single transcript, the probe with the most interquartile‐range variation across the samples, was retained in the analysis. Protein and phosphopeptide levels were assessed from 36 protein samples from the temporal cortex using SysQuant™ liquid chromatography tandem mass spectrometry (LC‐MS/MS) global proteomics (Proteome Sciences) as described.[26](#acn3639-bib-0026){ref-type="ref"}, [27](#acn3639-bib-0027){ref-type="ref"} LC‐MS/MS ‐based global proteomics identified 146,396 peptides mapping to 7516 unique proteins. The average of all peptide values mapping to a single protein were averaged to represent protein expression.

Clinical measurements {#acn3639-sec-0010}
---------------------

Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. BMI was calculated as weight (kg) divided by height (m) squared. The genotype groups did not significantly differ from each other in age or body mass index (BMI) (Table [1](#acn3639-tbl-0001){ref-type="table"}). In FINGER participants, current use of anti‐inflammatory drugs was verified at the screening/baseline visit (ATC codes M01A, M01B, B01AC06, H02A, and H02B for nonsteroids, corticosteroids, and their combinations). History of chronic inflammatory conditions was assessed based on self‐report of rheumatoid arthritis diagnosed by a physician, and ICD‐10 codes from the Finnish Hospital Discharge Register (K50‐51, L40, M05‐06, M10, M32‐35, and M45).

Laboratory measurements {#acn3639-sec-0011}
-----------------------

In METSIM cohort, plasma glucose was measured by enzymatic hexokinase photometric assay (Konelab Systems reagents, Thermo Fisher Scientific; Vantaa, Finland). Total cholesterol, low‐density cholesterol (LDL‐C), high‐density cholesterol (HDL‐C) and total triglycerides were measured by enzymatic colorimetric tests (Konelab Systems Reagents). Apolipoprotein B (ApoB) was determined by immunoturbidimetry (Konelab Systems Reagents). Plasma concentrations of high‐sensitivity C‐reactive protein (hs‐CRP) were assayed by kinetic immunoturbidimetry (NIPIA, Immage Immunochemistry System, Beckman Coulter, Fullerton, CA). Plasma interleukin‐1 receptor antagonist (IL‐1Ra) and interleukin‐1 *β* (IL‐1 *β*) were measured by immunoassay ELISA (R&D Systems Inc., Minneapolis, MN). All the above assays were performed on samples drawn after a 12‐h fasting. A*β*40 and A*β*42 in plasma were quantified with a fluorometric bead‐based immunoassay (INNO‐BIA plasma A*β* forms, Fujirebio Europe NV, Gent, Belgium) and analyzed on a Bio‐Plex 200 instrument (Bio‐Rad, California). Plasma samples used for A*β* measurement were 2 h samples from oral glucose tolerance test (OGTT).

In FINGER cohort, blood samples were drawn after overnight fasting (at least 10 h) at baseline visit. The separated serum and plasma samples were frozen immediately in −20°C and mailed monthly to the laboratory of the National Institute for Health and Welfare, where they were stored in −70°C. Serum cholesterol (total, LDL and HDL cholesterol), total triglycerides and plasma glucose levels were determined enzymatically using commercial reagents from Abbott Laboratories on a clinical chemistry analyzer Architect c8000 (Abbott Laboratories, Abbott Park, IL). ApoB was determined with immunoturbidimetric method on a clinical chemistry analyzer Architect c8000 (Abbott Laboratories). Circulating CRP levels were quantified from serum samples using a latex immunoassay (Sentinel Diagnostics, Milan, Italy) with Architect c8000 clinical chemistry analyzer (Abbott Laboratories). In the human postmortem brain samples, soluble A*β*42 levels were determined as described.[22](#acn3639-bib-0022){ref-type="ref"}

Statistical analysis {#acn3639-sec-0012}
--------------------

Due to skewed distributions, logarithmic transformation was used for all variables except for age and total and LDL cholesterol to achieve approximate normal distributions. Variables were compared across the *APOE* genotype groups by ANOVA or after adjustment for age (ANCOVA). Two‐way ANOVA was used to assess the main effects of the extent of AD‐related neurofibrillary pathology and *APOE* genotype on dependent variables. Fisher\'s least significant difference (LSD) posthoc analysis was performed for pairwise comparison. *APOE ε*3*ε*3 genotype group was considered as a reference group in pairwise comparisons. Spearman\'s rank correlation was used to assess correlations between the variables. Partial correlation controlling for age was used to assess the effect of age on the relation between plasma A*β*42 or A*β*42 and hs‐CRP levels. All statistical analyses were conducted with SPSS 21.0 software (SPSS, Chicago, IL). *P* \< 0.05 was considered as statistically significant except in the initial analysis with METSIM cohort, in which the threshold of statistical significance was set as *P* \< 0.0002 (*P* \< 0.05/248) given 248 cardiovascular health and metabolic parameters compared (Table [S1](#acn3639-sup-0001){ref-type="supplementary-material"}).[17](#acn3639-bib-0017){ref-type="ref"}, [28](#acn3639-bib-0028){ref-type="ref"}, [29](#acn3639-bib-0029){ref-type="ref"}

Results {#acn3639-sec-0013}
=======

A total of 248 cardiovascular health‐ and metabolism‐related parameters available in the METSIM cohort (Table [S1](#acn3639-sup-0001){ref-type="supplementary-material"})[17](#acn3639-bib-0017){ref-type="ref"}, [28](#acn3639-bib-0028){ref-type="ref"}, [29](#acn3639-bib-0029){ref-type="ref"} were analyzed in relation to *APOE* genotypes. As expected, all determined lipid and lipoprotein parameters differed significantly among the carriers of the different *APOE* genotypes (Table [1](#acn3639-tbl-0001){ref-type="table"}). Especially, LDL cholesterol in serum and ApoB in plasma differed significantly among the different *APOE* groups. The highest levels were observed among the *APOE ε*3*ε*4 and *ε*4*ε*4 individuals (Table [1](#acn3639-tbl-0001){ref-type="table"}). No significant differences were found in blood pressure or blood glucose parameters. The most significant difference was detected in hs*‐*CRP levels between the *APOE* genotypes (Table [1](#acn3639-tbl-0001){ref-type="table"}). In pairwise comparisons with *APOE ε*3*ε*3 genotype as the reference group, hs‐CRP levels were significantly lower in *ε*3*ε*4 (*P* = 4.93 x 10^−23^) and *ε*4*ε*4 (*P* = 4.15 x 10^−14^) group, but not in *ε*2*ε*2/*ε*2*ε*3 (*P* = 1.00) or *ε*2*ε*4 (*P* = 1.00) groups. *APOE* genotypes did not associate with the other inflammation‐related parameters available in the METSIM cohort, such as IL1‐RA or IL‐1*β* (Table [1](#acn3639-tbl-0001){ref-type="table"}). However, hs‐CRP levels significantly correlated with IL1‐RA (Spearman\'s rho = 0.285, *P* \< 0.0001). The significant association between *APOE* genotype and hs‐CRP persisted when individuals with likely ongoing acute infections (hs‐CRP \> 10 mg/L) were excluded from analyses (*n* = 4805, 98% of the cohort, *P* = 2.17 x 10^−31^ pairwise comparison with *APOE ε*3*ε*3 genotype as the reference group: *ε*2*ε*2/*ε*2*ε*3 (*P* = 1.00), *ε*2*ε*4 (*P* = 1.00), *ε*3*ε*4 (*P* = 4.41 x 10^−22^), and *ε*4*ε*4 (*P* = 3.94 × 10^−14^)). Since the levels of plasma A*β*40 and A*β*42 were previously determined in a subset of METSIM individuals,[10](#acn3639-bib-0010){ref-type="ref"} the plasma levels of these A*β* species were compared between individuals with *APOE ε*4 (*n* = 66) or without *APOE ε*4 (*n* = 149). However, there were no statistically significant differences between *APOE* groups (*APOE ε*4 + vs. *APOE ε*4^−^: A*β*40 *P* = 0.58 and A*β*42 *P* = 0.27). Correlation analyses of the plasma A*β*40 and A*β*42 levels with cardiovascular health‐ and metabolism‐related parameters available in the METSIM cohort revealed a positive correlation of A*β*40 (rho = 0.282, *P* = 2.7 x 10^−5^, *n* = 215), but not A*β*42 (rho = 0.076, *P* = 0.27, *n* = 214) with increased age (Fig. [1](#acn3639-fig-0001){ref-type="fig"}A and B). Moreover, the levels of plasma A*β*42 (rho = −0.148, *P* \< 0.05, *n* = 214), but not A*β*40 (rho = −0.059, *P* = 0.39, *n* = 215), negatively correlated with the levels of hs‐CRP (Figure [1](#acn3639-fig-0001){ref-type="fig"}C and D). Controlling for age in the A*β* and hs‐CRP correlation analyses revealed that age did not affect the observed outcome measures between plasma A*β*42 or A*β*40 and hs‐CRP levels (A*β*42: rho = −0.147, *P* \< 0.05, *n* = 214; A*β*40 rho = −0.051, *P* = 0.45, *n* = 215). Neither A*β*40 nor A*β*42 showed association with other inflammatory, lipid or lipoprotein parameters, blood pressure, or blood glucose metabolism parameters available.

![Correlation plots between plasma A*β*, hs‐CRP and age in the METSIM study. Plots showing correlation between A*β*40 and age (A), A*β*42 and age (B), A*β*40 and logarithmically transformed hs‐CRP(C) and A*β*42 and logarithmically transformed hs‐CRP (D) in the METSIM study.](ACN3-5-1229-g001){#acn3639-fig-0001}

To further study, the key findings observed in the METSIM cohort, lipid and inflammatory parameters were assessed among different *APOE* groups in the population‐based FINGER cohort consisting of both sexes (Table [2](#acn3639-tbl-0002){ref-type="table"}). Similar to the results in the METSIM, the levels of hs‐CRP, total cholesterol, LDL and ApoB differed between *APOE* groups and the levels being the highest in the individuals with *APOE ε*3*ε*4 and *ε*4*ε*4 genotypes (Table [2](#acn3639-tbl-0002){ref-type="table"}). Supporting the findings in the METSIM cohort, in pairwise comparisons with *APOE ε*3*ε*3 genotype as reference group, serum hs‐CRP levels were significantly lower in *ε*3*ε*4 (*P* = 0.017) and *ε*4*ε*4 (*P* = 1.00 x 10^−6^) groups, but not in *ε*2*ε*2/*ε*2*ε*3 (*P* = 0.49) or *ε*2*ε*4 (*P* = 0.33) groups. The result remained the same after adjustment for BMI and the use of anti‐inflammatory drugs, as well as after excluding the individuals with hs‐CRP\>10 mg/L (individuals with likely ongoing acute infection) and individuals with a history of chronic inflammatory conditions (total *n* = 1068, *P* \< 0.05 for *ε*3*ε*4, *P* \< 0.001 for *ε*4*ε*4, and statistically nonsignificant for *ε*2*ε*2/*ε*2*ε*3 or *ε*2*ε*4 groups). No significant differences were found in blood glucose parameters (fasting glucose or 2 h oral glucose tolerance test (OGTT)) between the *APOE* genotype groups.

Finally, a neuropathologically well‐characterized postmortem brain sample set[21](#acn3639-bib-0021){ref-type="ref"}, [22](#acn3639-bib-0022){ref-type="ref"}, [23](#acn3639-bib-0023){ref-type="ref"}was used to assess the local mRNA and/or protein levels of CRP and ApoB in the inferior temporal cortex in relation AD‐related neurofibrillary pathology (Braak staging)[24](#acn3639-bib-0024){ref-type="ref"}and *APOE* status. Two‐way ANOVA was conducted to compare the main effects of Braak and *APOE* status and the interaction effect between AD‐related neurofibrillary pathology and *APOE* status on mRNA and/or protein levels of CRP and ApoB. No statistically significant associations between CRP mRNA expression levels and neurofibrillary pathology (*P* = 0.78) or *APOE* genotype (*P* = 0.34) were observed. In addition, there was no significant association between AD‐related neurofibrillary pathology and *APOE* status (*P* = 0.40) (Fig. [2](#acn3639-fig-0002){ref-type="fig"}A). A significant association between protein levels of ApoB, but not mRNA levels, and AD‐related neurofibrillary pathology (RNA *P* = 0.13; Protein *P* = 0.02) was observed, irrespective of *APOE* genotype (AD‐related neurofibrillary pathology\**APOE* status interaction RNA *P* = 0.48; protein *P* = 0.54). No significant association between *APOE* genotype and *APOB* mRNA (*P* = 0.74) or protein levels (*P* = 0.13) was observed. Posthoc analysis revealed a significant increase in ApoB protein levels from mild to moderate group in the temporal cortex (*P* = 0.005) (Fig. [2](#acn3639-fig-0002){ref-type="fig"}B). Correlation analyses of CRP (CRP RNA rho = −0.089, *P* = 0.52, *n* = 55) and ApoB (ApoB protein rho = 0.124, *P* = 0.48, *n* = 36; *APOB* RNA rho = −0.018, *P* = 0.899, *n* = 55) with the levels of soluble A*β*42 in the temporal cortex were not statistically significant.

![Alterations of CRP and ApoB expression in the postmortem brain tissue with respect to neurofibrillary pathology. Brain CRP mRNA levels (A) and ApoB protein levels (B) in *APOE ε*4 carriers (*APOE ε*4^+^) and noncarriers (*APOE ε*4^−^) in the postmortem human temporal cortex with respect to AD‐related neurofibrillary pathology. The mean levels ± SD are indicated. Significant differences are denoted as: \*\* *P* ≤ 0.01.](ACN3-5-1229-g002){#acn3639-fig-0002}

Discussion {#acn3639-sec-0014}
==========

The *APOE ε*4 allele is the strongest genetic risk factor for AD.[30](#acn3639-bib-0030){ref-type="ref"} It is also associated with the risk of cardiovascular disease.[1](#acn3639-bib-0001){ref-type="ref"}, [6](#acn3639-bib-0006){ref-type="ref"} Here, we determined the association of different cardiovascular‐, metabolic health‐, and inflammation‐related parameters in relation to the different *APOE* genotypes in a large population‐based cohort (METSIM), consisting of nearly 5000 men from Eastern Finland. As expected, the highest lipid and lipoprotein levels, including those of total cholesterol, LDL and ApoB, were observed among the carriers of *APOE ε*4 allele. Three ApoE isoforms, encoded by *ε*2, *ε*3, and *ε*4 alleles in the *APOE* gene, differentially modulate plasma lipid and lipoprotein levels, and individuals carrying the *APOE ɛ*4 allele display higher total cholesterol levels in comparison to individuals with other isoforms[2](#acn3639-bib-0002){ref-type="ref"}, [6](#acn3639-bib-0006){ref-type="ref"} ^.^ Since approximately 90% of ApoB in plasma is normally bound to LDL, it is not surprising that the highest ApoB levels were detected among *APOE ɛ*4 allele carriers. Interestingly though, increased levels of serum ApoB have been shown to correlate with A*β*42 levels in the brain and increased serum ApoB levels have been reported among AD patients.[31](#acn3639-bib-0031){ref-type="ref"}, [32](#acn3639-bib-0032){ref-type="ref"} Accordingly, previous studies utilizing transgenic AD mouse models have shown that the overexpression of human ApoB promotes memory decline and increases lipid peroxidation, A*β* load, neurodegeneration, and astrogliosis in the brain.[33](#acn3639-bib-0033){ref-type="ref"}, [34](#acn3639-bib-0034){ref-type="ref"} Here, no data regarding A*β* levels in the brain or CSF were available from the participants of the METSIM study. Instead, we utilized a neuropathologically well‐established postmortem brain sample set to address ApoB‐related changes in the brain.[21](#acn3639-bib-0021){ref-type="ref"}, [22](#acn3639-bib-0022){ref-type="ref"}, [23](#acn3639-bib-0023){ref-type="ref"} A significant increase in ApoB at the protein, but not at the mRNA level, was detected in relation to advancing AD‐related neurofibrillary pathology, suggesting that ApoB is post‐translationally dysregulated or aberrantly transferred into the brain during the progression of AD‐type pathology. This finding was independent of the *APOE* status and no association between the levels of ApoB and A*β*42 in the brain was found. Nevertheless, data from our present study and others suggest that ApoB levels are altered in AD both in the brain and periphery, which warrants further mechanistic studies to elucidate the role of ApoB in cellular pathways involved in AD pathogenesis.

The most significant association in the METSIM cohort was found between the risk‐conferring *APOE ε*4 allele and lower levels of plasma hs‐CRP as compared to the other *APOE* alleles. Supporting the initial finding in the METSIM cohort, similar relationships between *APOE* genotypes and plasma hs‐CRP and ApoB levels was observed in the FINGER cohort consisting of approximately 1200 men and women.[18](#acn3639-bib-0018){ref-type="ref"} In general, the distribution of *APOE* genotypes was similar in both METSIM and FINGER cohorts as previously shown in the Finnish population.[35](#acn3639-bib-0035){ref-type="ref"} Importantly, the allele frequency of *APOE ε*4 was higher in these Finnish cohorts as compared to cohorts originating from the central Europe.[36](#acn3639-bib-0036){ref-type="ref"} This is consistent with the north‐south gradient, which has demonstrated that the *APOE ε*4 allele frequency is the highest in Finland and Sweden.[36](#acn3639-bib-0036){ref-type="ref"} Although the link between the *APOE ε*4 allele and low levels of plasma hs‐CRP is corroborated by several studies, most of the previous reports derive from considerably smaller cohorts, lacking convincing statistical power.[37](#acn3639-bib-0037){ref-type="ref"}, [38](#acn3639-bib-0038){ref-type="ref"}, [39](#acn3639-bib-0039){ref-type="ref"}, [40](#acn3639-bib-0040){ref-type="ref"}, [41](#acn3639-bib-0041){ref-type="ref"} To our knowledge, only one study has so far shown the link between *APOE* genotypes and hs‐CRP levels in a large population cohort of the same scale.[41](#acn3639-bib-0041){ref-type="ref"} Hence, our study provides important support for the evidence that *APOE ε*4 allele significantly associates with lower levels of plasma hs‐CRP levels. CRP is an important regulator of immune responses and it is commonly used as a biomarker for systemic inflammation. The presence of the *APOE ε*4 allele has been suggested to promote a pro‐inflammatory state in comparison to other *APOE* alleles.[3](#acn3639-bib-0003){ref-type="ref"}, [4](#acn3639-bib-0004){ref-type="ref"}, [5](#acn3639-bib-0005){ref-type="ref"} Thus, it is surprising that lower hs‐CRP levels, indicating lower levels of inflammation, are repeatedly detected among the individuals with the risk‐conferring *APOE ε*4 allele. Here, the observed association between *APOE* and hs‐CRP remained significant even after adjustments for possibly ongoing infection (hs‐CRP ≥10 mg/L), history of chronic inflammatory conditions, and ongoing anti‐inflammatory drug treatment. This suggests that the association is not explained by other concomitant inflammatory conditions or anti‐inflammatory drug treatment. Aside from hs‐CRP, *APOE* genotypes had no effect on the other inflammatory parameters available in the METSIM cohort. On the other hand, plasma hs‐CRP levels strongly correlated with the levels of IL1‐RA. As anti‐inflammatory effects of CRP are partially mediated through induction of IL1‐RA,[42](#acn3639-bib-0042){ref-type="ref"} this suggests that low hs‐CRP levels are linked with defective anti‐inflammatory responses.

Increased level of plasma hs‐CRP is a risk factor for cardiovascular disease, stroke, and diabetes, all of which are well‐established risk factors for AD.[41](#acn3639-bib-0041){ref-type="ref"}, [43](#acn3639-bib-0043){ref-type="ref"} Also, a direct link between elevated plasma hs‐CRP in midlife and a risk of AD and dementia has been described.[41](#acn3639-bib-0041){ref-type="ref"}, [43](#acn3639-bib-0043){ref-type="ref"} Inflammation is centrally involved in AD pathogenesis, as denoted by the presence of activated microglia and astrocytes as well as the increased levels of inflammatory molecules in the brain. A*β*42 is the key neurotoxic and pro‐inflammatory component in AD,[7](#acn3639-bib-0007){ref-type="ref"}, [8](#acn3639-bib-0008){ref-type="ref"} but recent studies have also pointed toward a potential anti‐inflammatory role for A*β*42 under certain conditions.[13](#acn3639-bib-0013){ref-type="ref"}, [14](#acn3639-bib-0014){ref-type="ref"} Since ApoE is the major mediator of A*β* clearance from the brain,[44](#acn3639-bib-0044){ref-type="ref"} we wanted to address potential changes in the plasma concentration of A*β* among different *APOE* groups. While plasma A*β*40 and A*β*42 levels remained unaffected between the different *APOE* groups*,* we observed a significant negative association between plasma A*β*42 and hs‐CRP levels even after age adjustment, suggesting that A*β*42 may confer protective effect(s) against peripheral inflammation. In this context, however, it should be noted that correlation between plasma A*β*42 and hs‐CRP was not particularly strong, indicating that significantly larger number of samples are still needed to comprehensively validate this relationship. Nevertheless, this finding is utmost importance, considering that A*β*42 has recently been suggested to participate in the defense response against pathogens, stress, and inflammatory conditions, in both the CNS and periphery.[13](#acn3639-bib-0013){ref-type="ref"}, [14](#acn3639-bib-0014){ref-type="ref"}, [45](#acn3639-bib-0045){ref-type="ref"}, [46](#acn3639-bib-0046){ref-type="ref"} Accordingly, decreased plasma hs‐CRP levels have been repeatedly reported among AD patients.[47](#acn3639-bib-0047){ref-type="ref"}, [48](#acn3639-bib-0048){ref-type="ref"}, [49](#acn3639-bib-0049){ref-type="ref"}, [50](#acn3639-bib-0050){ref-type="ref"} However, the relationship between the A*β* levels in plasma and CNS should be taken into consideration before further interpretations are made. Here, we were not able to address the observed plasma‐derived relationships, such as A*β* and hs‐CRP, in the CNS of METSIM and FINGER individuals, owing to lack of systematic A*β* pathology assessments. CRP has been demonstrated to localize to A*β* plaques in the brain of AD patients,[51](#acn3639-bib-0051){ref-type="ref"}, [52](#acn3639-bib-0052){ref-type="ref"} but its role in the CNS is not well known. In this study, we did not observe any alterations in the brain CRP mRNA levels at different stages of AD‐related neurofibrillary pathology among individuals with or without an *APOE ɛ*4 allele. Also, we did not find correlation between brain A*β*42 and CRP levels. It should also be emphasized that the overall mRNA expression of CRP in the temporal cortex was extremely low, suggesting that CRP does not have as a central role in CNS as in the periphery.

Taken together, we report here in exceptionally large population‐based cohorts a strong association between *APOE ɛ*4 allele and the levels of certain lipid, lipoprotein, and inflammatory parameters, which all may contribute to the risk of AD. The underlying cause and biological role of altered ApoB and hs‐CRP levels among *APOE ɛ*4 carriers and noncarriers in the etiology of AD and other relevant common diseases need to be addressed further in future mechanistic studies. In the light of recent studies demonstrating anti‐inflammatory potential for A*β*42, the observed association between peripheral A*β*42 levels and suppressed levels of plasma CRP is intriguing. Further investigations are required to understand the significance of this finding in the context of immune defense and AD.
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